Andrew Elliott Place, M.D., Ph.D.
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name | Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Precursor Cell Lymphoblastic Leukemia-Lymphoma | 9 | 2022 | 1458 | 2.210 |
Why?
|
| Asparaginase | 5 | 2022 | 218 | 1.160 |
Why?
|
| Bacillus | 1 | 2018 | 80 | 0.710 |
Why?
|
| Cataract | 1 | 2022 | 771 | 0.600 |
Why?
|
| Hematologic Neoplasms | 2 | 2018 | 1688 | 0.550 |
Why?
|
| Oleanolic Acid | 6 | 2005 | 52 | 0.530 |
Why?
|
| Polyethylene Glycols | 3 | 2021 | 1206 | 0.530 |
Why?
|
| Thrombocytopenia | 1 | 2022 | 1136 | 0.520 |
Why?
|
| Neutropenia | 1 | 2018 | 868 | 0.510 |
Why?
|
| Bacteremia | 1 | 2018 | 968 | 0.440 |
Why?
|
| Clinical Protocols | 1 | 2018 | 1470 | 0.440 |
Why?
|
| Antineoplastic Combined Chemotherapy Protocols | 7 | 2022 | 11269 | 0.400 |
Why?
|
| Antineoplastic Agents | 8 | 2018 | 13763 | 0.380 |
Why?
|
| Escherichia coli Proteins | 1 | 2015 | 1107 | 0.350 |
Why?
|
| Sulfonamides | 1 | 2018 | 1946 | 0.340 |
Why?
|
| Precursor B-Cell Lymphoblastic Leukemia-Lymphoma | 3 | 2018 | 199 | 0.340 |
Why?
|
| Neoplasm, Residual | 3 | 2022 | 1001 | 0.320 |
Why?
|
| Precursor T-Cell Lymphoblastic Leukemia-Lymphoma | 2 | 2021 | 379 | 0.320 |
Why?
|
| Neoplasm Recurrence, Local | 3 | 2021 | 8864 | 0.290 |
Why?
|
| Escherichia coli | 1 | 2015 | 4402 | 0.240 |
Why?
|
| Imidazoles | 3 | 2005 | 1279 | 0.230 |
Why?
|
| Infant | 11 | 2022 | 34274 | 0.230 |
Why?
|
| Child | 17 | 2022 | 73998 | 0.220 |
Why?
|
| Disease-Free Survival | 4 | 2022 | 7078 | 0.210 |
Why?
|
| Hematopoietic Stem Cell Transplantation | 1 | 2018 | 5125 | 0.210 |
Why?
|
| Child, Preschool | 12 | 2021 | 41195 | 0.210 |
Why?
|
| Leukemia, Myeloid, Acute | 3 | 2022 | 3283 | 0.210 |
Why?
|
| Leukemia | 2 | 2021 | 1504 | 0.200 |
Why?
|
| Adolescent | 14 | 2022 | 85327 | 0.200 |
Why?
|
| Lymphoma | 2 | 2022 | 1908 | 0.200 |
Why?
|
| Osteonecrosis | 1 | 2022 | 235 | 0.200 |
Why?
|
| Vancomycin Resistance | 1 | 2020 | 137 | 0.190 |
Why?
|
| Tumor Microenvironment | 1 | 2011 | 2963 | 0.190 |
Why?
|
| Galectins | 1 | 2021 | 243 | 0.180 |
Why?
|
| Remission Induction | 3 | 2020 | 2414 | 0.170 |
Why?
|
| Cholecalciferol | 1 | 2003 | 464 | 0.170 |
Why?
|
| Gene Expression Regulation, Leukemic | 2 | 2021 | 673 | 0.170 |
Why?
|
| Immune Evasion | 1 | 2021 | 332 | 0.170 |
Why?
|
| TOR Serine-Threonine Kinases | 2 | 2018 | 2118 | 0.170 |
Why?
|
| Vancomycin | 1 | 2020 | 512 | 0.160 |
Why?
|
| Fibroblasts | 3 | 2016 | 4312 | 0.150 |
Why?
|
| Neoplasms | 4 | 2020 | 20421 | 0.150 |
Why?
|
| Vincristine | 1 | 2018 | 1041 | 0.150 |
Why?
|
| Maximum Tolerated Dose | 1 | 2018 | 916 | 0.140 |
Why?
|
| Age Factors | 4 | 2018 | 18954 | 0.140 |
Why?
|
| Tissue Banks | 1 | 2016 | 198 | 0.140 |
Why?
|
| Intention to Treat Analysis | 1 | 2015 | 425 | 0.130 |
Why?
|
| Injections, Intramuscular | 1 | 2015 | 563 | 0.130 |
Why?
|
| Xenograft Model Antitumor Assays | 3 | 2021 | 3756 | 0.130 |
Why?
|
| Orthopedics | 1 | 2022 | 804 | 0.120 |
Why?
|
| Prednisone | 1 | 2018 | 1554 | 0.120 |
Why?
|
| Cyclin-Dependent Kinase 4 | 1 | 2016 | 535 | 0.120 |
Why?
|
| Leukemia, Myelogenous, Chronic, BCR-ABL Positive | 1 | 2018 | 683 | 0.120 |
Why?
|
| Purines | 1 | 2016 | 604 | 0.120 |
Why?
|
| Aminopyridines | 1 | 2016 | 538 | 0.120 |
Why?
|
| Neoplastic Stem Cells | 1 | 2021 | 1412 | 0.120 |
Why?
|
| Triterpenes | 2 | 2003 | 69 | 0.120 |
Why?
|
| Prognosis | 5 | 2022 | 29148 | 0.110 |
Why?
|
| Doxorubicin | 1 | 2018 | 2238 | 0.110 |
Why?
|
| Humans | 31 | 2022 | 709431 | 0.110 |
Why?
|
| Treatment Outcome | 6 | 2022 | 61963 | 0.100 |
Why?
|
| Canada | 1 | 2015 | 1933 | 0.100 |
Why?
|
| U937 Cells | 4 | 2005 | 282 | 0.100 |
Why?
|
| Single-Cell Analysis | 1 | 2021 | 2167 | 0.100 |
Why?
|
| Dose-Response Relationship, Drug | 3 | 2018 | 11384 | 0.100 |
Why?
|
| Gene Expression Profiling | 3 | 2016 | 9584 | 0.090 |
Why?
|
| Matrix Metalloproteinases | 1 | 2011 | 410 | 0.090 |
Why?
|
| Breast Neoplasms | 2 | 2016 | 19798 | 0.090 |
Why?
|
| Young Adult | 7 | 2022 | 56163 | 0.090 |
Why?
|
| Male | 14 | 2022 | 351848 | 0.080 |
Why?
|
| Calcium-Calmodulin-Dependent Protein Kinases | 2 | 1999 | 506 | 0.080 |
Why?
|
| Female | 16 | 2022 | 377269 | 0.080 |
Why?
|
| Research Design | 3 | 2018 | 5860 | 0.080 |
Why?
|
| Retrospective Studies | 5 | 2022 | 71151 | 0.080 |
Why?
|
| Nitric Oxide Synthase Type II | 3 | 2003 | 561 | 0.080 |
Why?
|
| Drug Resistance, Neoplasm | 2 | 2021 | 5227 | 0.080 |
Why?
|
| Recurrence | 1 | 2018 | 8279 | 0.070 |
Why?
|
| Clinical Trials, Phase III as Topic | 2 | 2020 | 811 | 0.070 |
Why?
|
| Proportional Hazards Models | 2 | 2022 | 12442 | 0.070 |
Why?
|
| Nitric Oxide Synthase | 3 | 2003 | 942 | 0.070 |
Why?
|
| Heme Oxygenase (Decyclizing) | 1 | 2005 | 167 | 0.070 |
Why?
|
| Adult | 8 | 2022 | 212298 | 0.070 |
Why?
|
| Kaplan-Meier Estimate | 1 | 2015 | 6830 | 0.060 |
Why?
|
| Incidence | 2 | 2022 | 20587 | 0.060 |
Why?
|
| Mitogen-Activated Protein Kinases | 2 | 1999 | 1331 | 0.060 |
Why?
|
| Trans-Activators | 2 | 2005 | 3060 | 0.060 |
Why?
|
| Leukocytes | 1 | 2011 | 2103 | 0.060 |
Why?
|
| Methyl Methanesulfonate | 2 | 1999 | 35 | 0.060 |
Why?
|
| Cytarabine | 2 | 2022 | 690 | 0.060 |
Why?
|
| Terpenes | 1 | 2003 | 114 | 0.060 |
Why?
|
| Inhibitory Concentration 50 | 1 | 2003 | 451 | 0.060 |
Why?
|
| Anti-Bacterial Agents | 1 | 2020 | 7071 | 0.060 |
Why?
|
| Protein Kinase Inhibitors | 1 | 2018 | 5392 | 0.050 |
Why?
|
| Medical Oncology | 1 | 2013 | 2070 | 0.050 |
Why?
|
| Models, Chemical | 1 | 2003 | 668 | 0.050 |
Why?
|
| Disease Progression | 2 | 2021 | 13298 | 0.050 |
Why?
|
| Neoplasm Metastasis | 1 | 2011 | 5168 | 0.050 |
Why?
|
| Cell Line, Tumor | 4 | 2016 | 17087 | 0.050 |
Why?
|
| Protein-Tyrosine Kinases | 2 | 1999 | 2463 | 0.050 |
Why?
|
| Epithelial Cells | 1 | 2011 | 3688 | 0.050 |
Why?
|
| Core Binding Factor Alpha 2 Subunit | 1 | 2021 | 352 | 0.050 |
Why?
|
| Receptors, Cytoplasmic and Nuclear | 1 | 2003 | 857 | 0.040 |
Why?
|
| Time Factors | 2 | 2015 | 41295 | 0.040 |
Why?
|
| Cell Division | 2 | 2003 | 4787 | 0.040 |
Why?
|
| Pediatrics | 1 | 2013 | 3556 | 0.040 |
Why?
|
| Germ Cells | 1 | 2021 | 572 | 0.040 |
Why?
|
| Randomized Controlled Trials as Topic | 3 | 2020 | 9504 | 0.040 |
Why?
|
| Cell Separation | 1 | 2003 | 1856 | 0.040 |
Why?
|
| Genomics | 1 | 2013 | 5250 | 0.040 |
Why?
|
| Ikaros Transcription Factor | 1 | 2018 | 227 | 0.040 |
Why?
|
| Nitriles | 1 | 2002 | 952 | 0.040 |
Why?
|
| Caspases | 1 | 2000 | 941 | 0.040 |
Why?
|
| Leukemia, Myeloid | 1 | 2000 | 735 | 0.040 |
Why?
|
| Drug Synergism | 2 | 2016 | 1890 | 0.040 |
Why?
|
| Transcriptional Activation | 1 | 2003 | 1843 | 0.040 |
Why?
|
| Molecular Targeted Therapy | 2 | 2021 | 2891 | 0.040 |
Why?
|
| Risk Assessment | 1 | 2018 | 23519 | 0.040 |
Why?
|
| Azacitidine | 1 | 2018 | 303 | 0.040 |
Why?
|
| Mitogen-Activated Protein Kinase Kinases | 1 | 1999 | 599 | 0.040 |
Why?
|
| DNA-Binding Proteins | 2 | 2005 | 9802 | 0.040 |
Why?
|
| B-Lymphocytes | 2 | 2021 | 4925 | 0.040 |
Why?
|
| Myeloid-Lymphoid Leukemia Protein | 1 | 2018 | 275 | 0.040 |
Why?
|
| Survival Rate | 2 | 2021 | 13363 | 0.040 |
Why?
|
| Leukemia, Experimental | 1 | 2016 | 262 | 0.040 |
Why?
|
| United States | 3 | 2021 | 67177 | 0.040 |
Why?
|
| Proto-Oncogene Proteins c-bcl-2 | 2 | 2000 | 1406 | 0.040 |
Why?
|
| Transforming Growth Factor beta | 1 | 2003 | 2003 | 0.030 |
Why?
|
| Follow-Up Studies | 3 | 2021 | 39394 | 0.030 |
Why?
|
| Quality of Life | 1 | 2015 | 11553 | 0.030 |
Why?
|
| Animals | 9 | 2016 | 170647 | 0.030 |
Why?
|
| Isoquinolines | 1 | 2016 | 388 | 0.030 |
Why?
|
| Leukocyte Count | 1 | 2018 | 1677 | 0.030 |
Why?
|
| Histone-Lysine N-Methyltransferase | 1 | 2018 | 681 | 0.030 |
Why?
|
| Dexamethasone | 2 | 2016 | 1937 | 0.030 |
Why?
|
| Multicenter Studies as Topic | 1 | 2018 | 1525 | 0.030 |
Why?
|
| Genes, p53 | 1 | 2016 | 775 | 0.030 |
Why?
|
| Proto-Oncogene Proteins c-mdm2 | 1 | 2016 | 387 | 0.030 |
Why?
|
| Monocytes | 1 | 2003 | 2662 | 0.030 |
Why?
|
| Nitric Oxide | 1 | 2002 | 2109 | 0.030 |
Why?
|
| Mice | 7 | 2016 | 80950 | 0.030 |
Why?
|
| Tumor Cells, Cultured | 1 | 2021 | 6659 | 0.030 |
Why?
|
| Risk Factors | 2 | 2018 | 70264 | 0.030 |
Why?
|
| Flow Cytometry | 1 | 2003 | 6185 | 0.030 |
Why?
|
| Neoplasm Transplantation | 1 | 2016 | 2190 | 0.030 |
Why?
|
| Mice, Inbred NOD | 1 | 2016 | 1935 | 0.030 |
Why?
|
| Random Allocation | 1 | 2016 | 2463 | 0.030 |
Why?
|
| Viral Proteins | 1 | 1999 | 1987 | 0.030 |
Why?
|
| Feasibility Studies | 1 | 2021 | 4903 | 0.030 |
Why?
|
| Salvage Therapy | 1 | 2018 | 1298 | 0.030 |
Why?
|
| Macrophages | 2 | 2003 | 5774 | 0.020 |
Why?
|
| Cell Differentiation | 3 | 2003 | 11749 | 0.020 |
Why?
|
| Administration, Oral | 1 | 2018 | 3952 | 0.020 |
Why?
|
| Focal Adhesion Kinase 2 | 2 | 1999 | 84 | 0.020 |
Why?
|
| Anti-Inflammatory Agents, Non-Steroidal | 1 | 1999 | 2268 | 0.020 |
Why?
|
| bcl-X Protein | 2 | 2000 | 405 | 0.020 |
Why?
|
| Bone Marrow | 1 | 2018 | 2939 | 0.020 |
Why?
|
| High-Throughput Nucleotide Sequencing | 1 | 2020 | 3718 | 0.020 |
Why?
|
| Cell Lineage | 1 | 2016 | 2632 | 0.020 |
Why?
|
| Mutation | 2 | 2021 | 29242 | 0.020 |
Why?
|
| Transcription Factors | 2 | 2003 | 11982 | 0.020 |
Why?
|
| Proteome | 1 | 2016 | 1747 | 0.020 |
Why?
|
| Phosphorylation | 3 | 2005 | 8737 | 0.020 |
Why?
|
| Prospective Studies | 2 | 2021 | 50734 | 0.020 |
Why?
|
| Piperazines | 1 | 2016 | 2606 | 0.020 |
Why?
|
| Enzyme Induction | 1 | 2005 | 517 | 0.020 |
Why?
|
| Survival Analysis | 1 | 2018 | 10603 | 0.020 |
Why?
|
| Multivariate Analysis | 1 | 2018 | 12517 | 0.020 |
Why?
|
| Mink | 1 | 2003 | 41 | 0.020 |
Why?
|
| Transfection | 2 | 2005 | 6193 | 0.020 |
Why?
|
| Response Elements | 1 | 2005 | 324 | 0.020 |
Why?
|
| Isoenzymes | 2 | 1999 | 1822 | 0.020 |
Why?
|
| Forecasting | 1 | 2013 | 2957 | 0.020 |
Why?
|
| Inflammation | 1 | 2003 | 9948 | 0.020 |
Why?
|
| Smad7 Protein | 1 | 2003 | 44 | 0.020 |
Why?
|
| Apoptosis | 1 | 2000 | 10133 | 0.020 |
Why?
|
| Internet | 1 | 2016 | 3076 | 0.020 |
Why?
|
| Neoplasm Proteins | 1 | 2016 | 3884 | 0.010 |
Why?
|
| Smad2 Protein | 1 | 2003 | 171 | 0.010 |
Why?
|
| NF-E2-Related Factor 2 | 1 | 2005 | 329 | 0.010 |
Why?
|
| Heme Oxygenase-1 | 1 | 2005 | 385 | 0.010 |
Why?
|
| Enzyme Activation | 2 | 1999 | 3904 | 0.010 |
Why?
|
| Cyclic AMP Response Element-Binding Protein | 1 | 2005 | 539 | 0.010 |
Why?
|
| p300-CBP Transcription Factors | 1 | 2003 | 153 | 0.010 |
Why?
|
| Promoter Regions, Genetic | 2 | 2005 | 6077 | 0.010 |
Why?
|
| Plasminogen Activator Inhibitor 1 | 1 | 2003 | 295 | 0.010 |
Why?
|
| Acetyltransferases | 1 | 2003 | 241 | 0.010 |
Why?
|
| Leukemia, Promyelocytic, Acute | 1 | 2003 | 237 | 0.010 |
Why?
|
| Receptors, Transforming Growth Factor beta | 1 | 2003 | 319 | 0.010 |
Why?
|
| Cyclic AMP | 1 | 2005 | 1532 | 0.010 |
Why?
|
| Histone Acetyltransferases | 1 | 2003 | 358 | 0.010 |
Why?
|
| Caspase 9 | 1 | 2000 | 200 | 0.010 |
Why?
|
| Caspase 8 | 1 | 2000 | 213 | 0.010 |
Why?
|
| DNA Fragmentation | 1 | 2000 | 251 | 0.010 |
Why?
|
| MAP Kinase Kinase 3 | 1 | 1999 | 27 | 0.010 |
Why?
|
| MAP Kinase Kinase 6 | 1 | 1999 | 25 | 0.010 |
Why?
|
| Vanadates | 1 | 1999 | 85 | 0.010 |
Why?
|
| HL-60 Cells | 1 | 2000 | 380 | 0.010 |
Why?
|
| PC12 Cells | 1 | 1999 | 346 | 0.010 |
Why?
|
| Transforming Growth Factor beta1 | 1 | 2003 | 654 | 0.010 |
Why?
|
| Protein Kinase C-delta | 1 | 1999 | 128 | 0.010 |
Why?
|
| T-Lymphocytes | 1 | 2016 | 10475 | 0.010 |
Why?
|
| Phosphotyrosine | 1 | 1999 | 473 | 0.010 |
Why?
|
| Signal Transduction | 4 | 2005 | 23985 | 0.010 |
Why?
|
| Phenotype | 1 | 2016 | 16295 | 0.010 |
Why?
|
| Osmolar Concentration | 1 | 1999 | 712 | 0.010 |
Why?
|
| Cohort Studies | 1 | 2021 | 39650 | 0.010 |
Why?
|
| Prostaglandin-Endoperoxide Synthases | 1 | 1999 | 353 | 0.010 |
Why?
|
| Caspase 3 | 1 | 2000 | 811 | 0.010 |
Why?
|
| Poly(ADP-ribose) Polymerases | 1 | 1999 | 439 | 0.010 |
Why?
|
| Serpins | 1 | 1999 | 272 | 0.010 |
Why?
|
| 3T3 Cells | 1 | 1999 | 1129 | 0.010 |
Why?
|
| Molecular Structure | 1 | 2002 | 2020 | 0.010 |
Why?
|
| Antioxidants | 1 | 2005 | 1687 | 0.010 |
Why?
|
| JNK Mitogen-Activated Protein Kinases | 1 | 1999 | 469 | 0.010 |
Why?
|
| Middle Aged | 2 | 2022 | 215428 | 0.010 |
Why?
|
| Clinical Trials as Topic | 1 | 2013 | 8053 | 0.010 |
Why?
|
| Protein Tyrosine Phosphatases | 1 | 1999 | 489 | 0.010 |
Why?
|
| Cyclooxygenase 2 | 1 | 1999 | 627 | 0.010 |
Why?
|
| Antimetabolites, Antineoplastic | 1 | 2000 | 660 | 0.010 |
Why?
|
| Structure-Activity Relationship | 1 | 2002 | 3221 | 0.010 |
Why?
|
| p38 Mitogen-Activated Protein Kinases | 1 | 1999 | 738 | 0.010 |
Why?
|
| Membrane Proteins | 2 | 2005 | 8101 | 0.010 |
Why?
|
| Ultraviolet Rays | 1 | 1999 | 1071 | 0.010 |
Why?
|
| Protein Kinase C | 1 | 1999 | 1295 | 0.010 |
Why?
|
| Oxidative Stress | 1 | 2005 | 3152 | 0.010 |
Why?
|
| Interferon-gamma | 1 | 2002 | 3319 | 0.010 |
Why?
|
| Cisplatin | 1 | 1999 | 1663 | 0.010 |
Why?
|
| Rats | 2 | 1999 | 25068 | 0.010 |
Why?
|
| Stress, Physiological | 1 | 1999 | 1432 | 0.010 |
Why?
|
| Cell Cycle Proteins | 1 | 2003 | 3513 | 0.010 |
Why?
|
| Aged | 1 | 2021 | 162592 | 0.010 |
Why?
|
| RNA, Messenger | 1 | 2003 | 13351 | 0.010 |
Why?
|
| Lung | 1 | 2003 | 9617 | 0.000 |
Why?
|
| Cell Line | 1 | 1999 | 16795 | 0.000 |
Why?
|